[Clinical Outcomes of Transurethral Water Vapor Energy Therapy with Rezumᵀᴹ System]

We carefully reviewed and evaluated the efficacy of transurethral water vapor energy therapy (WAVE) with Rezumᵀᴹ system for treatment of benign prostatic hyperplasia. Between April and September 2023, 41 patients received WAVE under local anesthesia as day surgery at the outpatient department in our institution. The mean age as of operation was 78.7 years, and mean estimated prostatic volume was 42.3 ml. The median total operative time was 2 minutes, median puncture number of time was 3 times, and median duration of urethral catheter day was 7 days. The International Prostate Symptom Score (IPSS), quality of life (QOL) index, and maximum flow rate (Qmax) were assessed preoperatively and at 1 and 3 months postoperatively. In this evaluation, IPSS and QOL index improved significantly at 1 month postoperatively (IPSS : p＝0.023, QOL index : p＜0.001). Although Qmax was not significantly different between preoperative and 1 month postoperatively (p＝0. 167), a significant difference was shown at 3 months postoperatively (p＝0.006). Objective test findings such as Qmax required more than 1 month to improve. Subjective symptoms such as IPSS and QOL index improved in an early postoperative period. In conclusion, WAVE is an effective procedure for the treatment of benign prostatic hyperplasia.